National Health Investors (NHI) Projected to Release Quarterly Earnings on Monday

National Health Investors (NYSE:NHI) will likely be issuing its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect National Health Investors to post earnings of $0.8430 per share and revenue of $72.1240 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

National Health Investors Price Performance

NHI stock opened at $76.81 on Monday. The company has a debt-to-equity ratio of 0.83, a current ratio of 8.20 and a quick ratio of 8.20. The company’s 50-day moving average is $75.13 and its 200-day moving average is $79.75. The stock has a market capitalization of $3.72 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 3.44 and a beta of 0.51. National Health Investors has a 1 year low of $67.94 and a 1 year high of $91.38.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on NHI shares. BMO Capital Markets dropped their price target on National Health Investors from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Monday, June 15th. Truist Financial reduced their price objective on National Health Investors from $89.00 to $81.00 and set a “buy” rating for the company in a research note on Friday, June 12th. Wells Fargo & Company decreased their price objective on National Health Investors from $84.00 to $79.00 and set an “equal weight” rating for the company in a report on Monday, June 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $94.00 target price on shares of National Health Investors in a research report on Wednesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft cut their target price on National Health Investors from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, June 25th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, National Health Investors has an average rating of “Moderate Buy” and an average target price of $83.86.

Insider Transactions at National Health Investors

In related news, Director Robert A. Mccabe, Jr. acquired 890 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was purchased at an average cost of $71.65 per share, with a total value of $63,768.50. Following the acquisition, the director owned 44,159 shares of the company’s stock, valued at approximately $3,163,992.35. This trade represents a 2.06% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO D. Eric Mendelsohn acquired 1,500 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were bought at an average cost of $68.84 per share, with a total value of $103,260.00. Following the completion of the acquisition, the chief executive officer directly owned 133,316 shares in the company, valued at approximately $9,177,473.44. This represents a 1.14% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On National Health Investors

Several institutional investors have recently bought and sold shares of the stock. Freestone Grove Partners LP bought a new stake in shares of National Health Investors during the 4th quarter worth $21,869,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of National Health Investors in the 4th quarter worth about $19,856,000. Balyasny Asset Management L.P. grew its position in National Health Investors by 66.9% during the second quarter. Balyasny Asset Management L.P. now owns 614,960 shares of the real estate investment trust’s stock valued at $43,121,000 after buying an additional 246,486 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in National Health Investors by 481.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 236,383 shares of the real estate investment trust’s stock valued at $18,792,000 after buying an additional 195,716 shares during the period. Finally, Qube Research & Technologies Ltd increased its holdings in National Health Investors by 86.0% during the second quarter. Qube Research & Technologies Ltd now owns 319,286 shares of the real estate investment trust’s stock worth $22,388,000 after buying an additional 147,591 shares during the last quarter. Institutional investors own 62.51% of the company’s stock.

About National Health Investors

National Health Investors, Inc (NYSE: NHI) is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company’s portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.